- [Heart Valve Disease - update ESC guideline 2017]. [Journal Article]
- DMDtsch Med Wochenschr 2018; 143(24):1765-1769
- Surgical management of patients with aortic valve stenosis is declining and Transcatheter aortic valve implantation (TAVI) is becoming the treatment of choice in many patients. The ESC guideline inte...
Surgical management of patients with aortic valve stenosis is declining and Transcatheter aortic valve implantation (TAVI) is becoming the treatment of choice in many patients. The ESC guideline integrated results of randomized controlled trials in patients with intermediate surgical risk for the first time. TAVI showed good and comparable results to the standard surgical approach.Mitral regurgitation (MR) is a complex disease with good surgical results in primary MR and mixed results in secondary MR. Secondary MR is mainly based on left ventricular disease with subsequent dilatation. Interventional treatment with edge-to-edge-repair (Mitraclip) is an alternative therapeutic approach in patients with high surgical risk.The recommendation on treatment of concomitant coronary artery disease in patients with valvular heart disease was updated based on recent scientific results. Proximal coronary artery stenosis ≥ 70 % should be treated by percutaneous coronary intervention before TAVI or alternatively simultaneous surgical bypass grafting during valve surgery should be performed.Due to increasing interventional and surgical therapeutic options for the treatment of all four heart valves, the Heart Team is of upmost importance. The cardiologist and the cardiac surgeon should analyse all diagnostic and therapeutic results and see the patient. Colleagues of other specialities should join the team if necessary. There are several recommended requirements for heart valve centres defined in the guideline. The primary goal is excellent and individualized patient care.
- Transcatheter aortic valve replacement in patients with bicuspid aortic valves. [Review]
- JTJ Thorac Dis 2018; 10(Suppl 30):S3568-S3572
- Transcatheter aortic valve replacement (TAVR) for the treatment of severe symptomatic aortic stenosis (AS) has rapidly become the standard of care for expanding clinical indications based on the resu...
Transcatheter aortic valve replacement (TAVR) for the treatment of severe symptomatic aortic stenosis (AS) has rapidly become the standard of care for expanding clinical indications based on the results of multiple large-scale randomized trials. Patients with bicuspid aortic valve (BAV) have been largely excluded from these trials for a variety of reasons. However, case series and registry data has shown TAVR in BAV to be a safe and efficacious alternative to surgical aortic valve replacement (SAVR) with the possible caveats of increased paravalvular regurgitation (PVR) and need for permanent pacemaker (PPM) implantation. Randomized trials are needed to determine the ultimate utility of TAVR in patients with BAV.
- Simultaneously surgical management of adult complex coarctation of aorta concomitant with intracardiac abnormality. [Journal Article]
- JTJ Thorac Dis 2018; 10(10):5842-5849
- CONCLUSIONS: Simultaneous management of complex COA concomitant with intracardiac abnormality is a safe and reliable surgical method.
- The CHOICE Between Self-Expanding and Balloon-Expandable Valves for Transcatheter Aortic Valve Replacement. [Editorial]
- JCJACC Cardiovasc Interv 2018 Nov 23
- Bioprosthetic Valve Performance After Transcatheter Aortic Valve Replacement With Self-Expanding Versus Balloon-Expandable Valves in Large Versus Small Aortic Valve Annuli: Insights From the CHOICE Trial and the CHOICE-Extend Registry. [Journal Article]
- JCJACC Cardiovasc Interv 2018 Nov 23
- CONCLUSIONS: Older-generation balloon-expandable THVs were associated with less PVR than self-expanding THVs in patients with large but not small annuli. The next-generation self-expanding THV has improved sealing in patients with large annuli and may have potential advantages in patients with small annuli.
- Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation: A Systematic Review. [Review]
- CCardiology 2018 Dec 05; 141(3):132-140
- CONCLUSIONS: Aortic regurgitation remains a challenging pathology for TAVR. TAVR is a feasible and reasonable option for carefully selected patients with pure aortic regurgitation.
- Comment on "Transcatheter Aortic Valve Replacement in Patients with Pure Native Aortic Valve Regurgitation: A Systematic Review and Meta-analysis". [Letter]
- CCClin Cardiol 2018 Dec 05
- The timely publication by Haddad et al. entitled "Transcatheter Aortic Valve Replacement in Patients with Pure Native Aortic Valve Regurgitation: A Systematic Review and Meta-analysis" in the journal...
The timely publication by Haddad et al. entitled "Transcatheter Aortic Valve Replacement in Patients with Pure Native Aortic Valve Regurgitation: A Systematic Review and Meta-analysis" in the journal Clinical Cardiology addresses one of the topics which is receiving increasing attention in cardiovascular intervention field .
- Impact of Tricuspid Regurgitation and Right Ventricular Dysfunction on Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. [Review]
- CCClin Cardiol 2018 Dec 04
- CONCLUSIONS: Both baseline moderate or severe TR and RV dysfunction worsen prognosis after TAVR and careful assessment of right heart function should be done for clinical decision by the heart team before the TAVR procedure.
- Aortic disease and interventions in adults with tetralogy of Fallot. [Journal Article]
- HHeart 2018 Dec 04
- CONCLUSIONS: Although aortic aneurysm was common, progressive aortic dilation was uncommon and aortic dissection did not occur in our patients with TOF with significant aortic aneurysms who did not undergo aortic surgery. This has important clinical implication in deciding the frequency of imaging follow-up and timing of surgical intervention in this population.
New Search Next
- The Multivalvular Score for Predicting the Outcome of Mitral Regurgitation in Aortic Stenosis Patients Treated With TAVI: Prospective Validation. [Journal Article]
- RERev Esp Cardiol (Engl Ed) 2018 Dec 01